Hypertrophic cardiomyopathy electrophysiologic testing: Difference between revisions
Created page with "__NOTOC__ {{Hypertrophic cardiomyopathy}} {{CMG}} ==Overview== The prognostic value of electrophysiologic testing in the absence of spontaneous, sustained ventricular tachyca..." |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The prognostic value of electrophysiologic testing in the absence of spontaneous, sustained ventricular tachycardia is limited, and in fact, the study itself may be dangerous. Sustained ventricular tachyarrhythmias, predominantly rapid polymorphic ventricular tachycardia, have been induced in 27 to 43 percent of patients with HCM at electrophysiologic study, but their prognostic significance is controversial. The predictive value of asymptomatic nonsustained ventricular tachycardia is also limited. Paced electrogram fractionation in hypertrophic cardiomyopathy may helpful in determining which patients are at risk for [[ventricular fibrillation]]. | The prognostic value of electrophysiologic testing in the absence of spontaneous, sustained [[ventricular tachycardia]] is limited, and in fact, the study itself may be dangerous. Sustained ventricular tachyarrhythmias, predominantly rapid [[polymorphic ventricular tachycardia]], have been induced in 27 to 43 percent of patients with HCM at electrophysiologic study, but their prognostic significance is controversial. The predictive value of asymptomatic [[nonsustained ventricular tachycardia]] is also limited. [[Paced electrogram fractionation]] in hypertrophic cardiomyopathy may helpful in determining which patients are at risk for [[ventricular fibrillation]]. | ||
The absence of inducible, sustained monomorphic ventricular tachyarrhythmias, absence of nonsustained ventricular tachycardia on ambulatory ECG, and no history of ''impaired consciousness'' (i.e., cardiac arrest or syncope) identified a subset (22 percent) of patients with HCM with a low (<1 percent) risk for sudden cardiac death. | The absence of inducible, sustained [[monomorphic ventricular tachyarrhythmias]], absence of [[nonsustained ventricular tachycardia]] on [[ambulatory ECG]], and no history of ''impaired consciousness'' (i.e., [[cardiac arrest]] or [[syncope]]) identified a subset (22 percent) of patients with HCM with a low (<1 percent) risk for [[sudden cardiac death]]. | ||
==References== | ==References== | ||
Revision as of 03:08, 6 September 2013
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy electrophysiologic testing On the Web |
|
FDA on Hypertrophic cardiomyopathy electrophysiologic testing |
|
CDC on Hypertrophic cardiomyopathy electrophysiologic testing |
|
Hypertrophic cardiomyopathy electrophysiologic testing in the news |
|
Blogs on Hypertrophic cardiomyopathy electrophysiologic testing |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy electrophysiologic testing |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The prognostic value of electrophysiologic testing in the absence of spontaneous, sustained ventricular tachycardia is limited, and in fact, the study itself may be dangerous. Sustained ventricular tachyarrhythmias, predominantly rapid polymorphic ventricular tachycardia, have been induced in 27 to 43 percent of patients with HCM at electrophysiologic study, but their prognostic significance is controversial. The predictive value of asymptomatic nonsustained ventricular tachycardia is also limited. Paced electrogram fractionation in hypertrophic cardiomyopathy may helpful in determining which patients are at risk for ventricular fibrillation.
The absence of inducible, sustained monomorphic ventricular tachyarrhythmias, absence of nonsustained ventricular tachycardia on ambulatory ECG, and no history of impaired consciousness (i.e., cardiac arrest or syncope) identified a subset (22 percent) of patients with HCM with a low (<1 percent) risk for sudden cardiac death.